Creo Medical Limited
CREO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £4 | £31 | £27 | £25 |
| % Growth | -87% | 13.4% | 8% | – |
| Cost of Goods Sold | £2 | £16 | £17 | £16 |
| Gross Profit | £2 | £15 | £10 | £9 |
| % Margin | 47.5% | 49.7% | 36.8% | 35.9% |
| R&D Expenses | £11 | £12 | £14 | £13 |
| G&A Expenses | £30 | £41 | £44 | £42 |
| SG&A Expenses | £30 | £41 | £27 | £26 |
| Sales & Mktg Exp. | £0 | £0 | -£17 | -£15 |
| Other Operating Expenses | -£11 | -£12 | £0 | £0 |
| Operating Expenses | £31 | £40 | £41 | £39 |
| Operating Income | -£29 | -£25 | -£31 | -£30 |
| % Margin | -720% | -80.5% | -113.4% | -119.1% |
| Other Income/Exp. Net | -£0 | £1 | -£0 | -£0 |
| Pre-Tax Income | -£29 | -£25 | -£31 | -£30 |
| Tax Expense | -£1 | -£3 | -£4 | -£6 |
| Net Income | -£29 | -£22 | -£27 | -£25 |
| % Margin | -717.5% | -70.5% | -99.1% | -97.8% |
| EPS | -0.079 | -0.069 | -0.14 | -0.14 |
| % Growth | -14.6% | 50.5% | 0% | – |
| EPS Diluted | -0.079 | -0.069 | -0.14 | -0.14 |
| Weighted Avg Shares Out | 362 | 313 | 188 | 170 |
| Weighted Avg Shares Out Dil | 362 | 313 | 188 | 170 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £1 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £3 | £3 | £3 | £3 |
| EBITDA | -£26 | -£21 | -£28 | -£28 |
| % Margin | -652.5% | -67.2% | -101.6% | -109.5% |